Trial Profile

A Follow-up Study to Evaluate the Long-term Post Treatment Effects of Peginterferon Alfa-2a (PEG-IFN) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study WV19432 (NEPTUNE).

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Apr 2016 Results (n=383) assessing HBeAg seroconversion (SC) rates 5 years after completion of treatment were presented at The International Liver Congress™ 2016.
10 Feb 2016 Treatment arm (from 1 to 4), design keyword (randomised & parallel), inclusion and exclusion criteria have been changed, as reported by ClinicalTrial.gov record.
08 Dec 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com